STOCK TITAN

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

NervGen (NGEN) reported third-quarter 2026 results with a wider net loss as enrollment continued in its Phase 3 RESTORE study.

Cash was C$80.1 million at September 30, versus C$22.1 million at December 31, 2025. The company expects this to fund operations through RESTORE’s anticipated first-half 2028 topline results. Quarterly net loss was C$6.4 million versus C$4.7 million a year earlier; research and development expenses rose to C$7.9 million from C$4.3 million.

RESTORE’s first participant was dosed in October 2026, with enrollment completion expected in the second half of 2027. NVG-291 received FDA Breakthrough Therapy designation for chronic traumatic cervical motor-incomplete spinal cord injury. NervGen plans to request a multidisciplinary Type B FDA meeting to discuss development and opportunities to expedite the program. It completed a non-cash financial restatement in October 2026.

Loading...
Loading translation...
9 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointC$80.1 million cash at September 30, 2026, versus C$22.1 million at December 31, 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway expected to cover operations through anticipated RESTORE topline results in the first half of 2028.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.RESTORE enrollment ongoing after first dosing in October 2026; completion expected in the second half of 2027.
  • Moderate pointFDA Breakthrough Therapy designation granted to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional RESTORE sites activated, including designated SCI Model Systems centers; further centers are being prepared.
4 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Type B FDA meeting request planned to discuss continued NVG-291 development and opportunities to expedite the program.
  • Minor pointPreliminary embryofetal development studies completed successfully, advancing nonclinical work supporting readiness for a New Drug Application.
  • Minor point. Forward-looking: it has not happened yet and may not happen.CONNECT SCI manuscript is in final preparation for submission to a peer-reviewed journal.
  • Minor pointC$4.4 million non-cash warrant derivative gain in third-quarter 2026, versus C$0.8 million a year earlier.

Negative

  • Moderate pointThird-quarter net loss widened to C$6.4 million in 2026 from C$4.7 million in 2025.
  • Moderate pointResearch and development expenses rose to C$7.9 million in third-quarter 2026 from C$4.3 million a year earlier.
  • Minor pointGeneral and administrative expenses rose to C$3.3 million in third-quarter 2026 from C$1.3 million a year earlier.

News Explained

NervGen reports no shares sold under its ATM through November 16, 2026, and plans to terminate it on December 25, 2026; the program permits gradual new-share sales at market prices, which would dilute existing holders if used.

Key Figures

Cash and cash equivalents: C$80.1 million (US$56.5 million) Cash runway: Through anticipated RESTORE topline readout in 1H 2028 R&D expenses: C$7.9 million +4 more
Cash and cash equivalents
C$80.1 million (US$56.5 million)
As of September 30, 2026; versus C$22.1 million (US$16.1 million) as of December 31, 2025
Cash runway
Through anticipated RESTORE topline readout in 1H 2028
Based on the company’s current operating plan
R&D expenses
C$7.9 million
Three months ended September 30, 2026; compared with C$4.3 million in the same period of 2025
G&A expenses
C$3.3 million
Three months ended September 30, 2026; compared with C$1.3 million in the same period of 2025
Net loss
C$6.4 million
Three months ended September 30, 2026; C$0.06 per weighted-average common share, basic and diluted
Unrealized gain on warrant derivatives
C$4.4 million
Non-cash gain included in the quarter’s net loss; compared with C$0.8 million in the same period of 2025
RESTORE topline data
1H 2028
Anticipated readout timing

Previous Earnings Reports

1 past event · Latest: Aug 13
Same Type 1 event
  1. Aug 13

    Earnings report

    24h Move
    +0.0%

    Reported cash runway through RESTORE topline data and continued Phase 3 preparation

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

breakthrough therapy designation, new drug application, at-the-market, u.s. gaap
4 terms
breakthrough therapy designation regulatory
"The U.S. Food and Drug Administration (FDA) granted NVG-291 Breakthrough Therapy designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
new drug application regulatory
"supporting New Drug Application (NDA) readiness"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
at-the-market financial
"no common shares have been sold under the Company’s at-the-market (ATM) program"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
u.s. gaap financial
"prepare its financial statements under U.S. GAAP"
U.S. GAAP is a set of rules and standards that companies in the United States follow to prepare their financial reports. It helps ensure that financial information is consistent and clear, so investors and others can compare and understand a company's financial health easily.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Company plans to request a multidisciplinary Type B meeting with FDA to discuss NVG-291’s continued development and opportunities to expedite the program following Breakthrough Therapy designation
  • Enrollment ongoing in the Phase 3 RESTORE study, with continued activation of additional clinical sites, including designated SCI Model Systems centers
  • Phase 1b/2a CONNECT SCI manuscript in final preparation for submission to a peer-reviewed journal
  • Well-funded with C$80.1 million (US$56.5 million) in cash as of September 30, 2026, expected to fund operations through anticipated RESTORE topline readout in 1H 2028

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

“Today, NervGen is actively enrolling participants in RESTORE under an FDA-aligned Phase 3 registrational design, and NVG-291 has received FDA Breakthrough Therapy designation, reinforcing its therapeutic potential, supported by promising preliminary clinical evidence from CONNECT SCI,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen. “During the third quarter, we were honored to join the SCI community as an industry sponsor of the first-ever externally led SCI Patient-Focused Drug Development meeting, held during SCI Awareness Month to help ensure community perspectives inform ongoing and future treatment development. Additionally, at our inaugural R&D Day, we highlighted the scientific and clinical foundation for NVG-291 and its potential as a pipeline-in-a-product. As NervGen continues to grow and RESTORE enrollment advances, we remain steadfast in our commitment to rigorous oversight, working closely with investigators and site staff to maintain high standards of study execution.”

Third Quarter 2026 and Recent Business Highlights

Phase 3 RESTORE Study

  • Enrollment is ongoing following dosing of the first participant in October 2026. The Company continues to expect completion of enrollment in the second half of 2027, with topline data in the first half of 2028.
  • Site activation continues, including the recent activation of designated SCI Model Systems centers. The Company is working closely with investigators and site staff to prepare additional centers to open on a rolling basis.

Regulatory and Development Progress

  • The U.S. Food and Drug Administration (FDA) granted NVG-291 Breakthrough Therapy designation for the treatment of chronic traumatic cervical motor-incomplete SCI. The designation is based on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating that NVG-291 may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints.
  • Advanced the nonclinical program supporting New Drug Application (NDA) readiness, including successful completion of preliminary embryofetal development studies. A chronic toxicology study is ongoing as part of the broader work intended to support dosing of NVG-291 beyond 12 weeks and future clinical expansion.

Scientific and Community Engagement

  • The Company is finalizing a manuscript reporting results from the Phase 1b/2a CONNECT SCI study for submission to a peer-reviewed journal.
  • Supported the first externally led SCI Patient-Focused Drug Development meeting, held on September 29, 2026, as an industry sponsor. The meeting drew more than 1,000 registrants and gathered community perspectives on living with SCI and treatment priorities to inform a Voice of the Patient report for the FDA and treatment developers. A recording is available at www.scipfdd.org.
  • Hosted NervGen’s inaugural R&D Day on September 30, 2026. Four leading SCI experts joined management to discuss NVG-291’s scientific rationale, clinical findings, and broader therapeutic potential, as well as the Phase 3 RESTORE study. A replay is available under “Events & Presentations” at www.nervgen.com.

Corporate

  • The Company expects to report as a U.S. domestic filer and prepare its financial statements under U.S. GAAP, beginning with its Annual Report on Form 10-K for fiscal year 2026.

Upcoming Investor Conference

  • Management will attend and participate in the 9th Annual Evercore Healthcare Conference, taking place November 30 to December 2, 2026, in Coral Gables, Florida.

Third Quarter 2026 Financial Results

Cash and Investments. As of September 30, 2026, NervGen had cash and cash equivalents of C$80.1 million (US$56.5 million), compared to C$22.1 million (US$16.1 million) as of December 31, 2025. Based on its current operating plan, the Company believes that its cash and cash equivalents as of September 30, 2026, will be sufficient to fund its operations through the anticipated topline data readout from RESTORE in 1H 2028. Through the date of this release, no common shares have been sold under the Company’s at-the-market (ATM) program. The ATM program will be terminated on December 25, 2026, in advance of the Company’s expected transition to U.S. domestic issuer reporting status.

Research & Development (R&D). R&D expenses were C$7.9 million for the three months ended September 30, 2026, compared to C$4.3 million for the same period in 2025. The increase was primarily attributable to clinical and regulatory costs associated with the initiation of RESTORE, completion of preliminary embryofetal development studies, the ongoing chronic toxicology study, and manufacturing of drug substance and drug product to supply RESTORE.

General and Administrative (G&A). G&A expenses were C$3.3 million for the three months ended September 30, 2026, compared to C$1.3 million for the same period in 2025. The increase was primarily attributable to higher non-cash stock-based compensation expense, higher directors’ and officers’ liability insurance premiums following the Company’s Nasdaq listing, and higher audit and legal fees.

Net Loss. Net loss for the three months ended September 30, 2026, was C$6.4 million, or C$0.06 per weighted-average common share outstanding (basic and diluted), compared to a net loss of C$4.7 million, or C$0.06 per weighted-average common share outstanding (basic) and C$0.07 per weighted-average common share outstanding (diluted), for the same period in 2025. Net loss for the period includes a C$4.4 million non-cash unrealized gain on the warrant derivatives, compared to a C$0.8 million non-cash unrealized gain on the warrant derivatives for the same period in 2025. The warrant derivatives are remeasured each reporting period, with changes in fair value recognized as non-cash gains or losses that do not affect the Company’s cash balance.

Restatement. In October 2026, the Company completed the previously announced restatement of its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the three and six months ended June 30, 2026. The restatement revised the valuation of certain warrants and options and the accounting for share issuance costs. The adjustments were non-cash and had no impact on the Company’s cash and cash equivalents, cash runway, or business operations.

The Company’s financial statements for the quarter ended September 30, 2026, and the related management’s discussion and analysis (MD&A) will be available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar.

About the Phase 3 RESTORE Study
RESTORE is a multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating the efficacy and safety of NVG-291 in adults living with chronic traumatic cervical motor-incomplete SCI. The study is expected to enroll approximately 150 participants across the United States and Canada. The study’s primary endpoint assesses improvement in hand function, a leading recovery priority for individuals with cervical SCI, as measured by GRASSP Quantitative Prehension. Secondary endpoints and blinded participant interviews will provide additional insight into functional independence and quality of life. Eligible participants are one to ten years following a traumatic SCI, have a motor level at C7 or higher on both sides and have an American Spinal Injury Association (ASIA) Impairment Scale classification of C or D. Participants will be randomized 1:1 to receive NVG-291 or placebo by once-daily subcutaneous injection for 12 weeks, followed by a four-week observation period. An optional 12-week open-label extension is planned following study completion. For additional information, including eligibility criteria and study locations, visit ClinicalTrials.gov (identifier: NCT07799532).

About NervGen
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Breakthrough Therapy designation from the FDA for the treatment of chronic traumatic cervical motor-incomplete SCI. It has also received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and its next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Statements regarding the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, and other future events or developments constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the design, conduct and anticipated timelines of the RESTORE study, including expected enrollment, activation of additional sites, completion of enrollment, timing of topline data and the planned open-label extension; the Company’s planned request for a multidisciplinary Type B meeting with the FDA to discuss NVG-291’s continued development and opportunities to expedite the program following Breakthrough Therapy designation; the sufficiency of the Company’s cash resources and the period into which they are expected to fund operations; the termination of the Company’s ATM program upon expiration of the Company’s base shelf prospectus and transition to U.S. domestic issuer reporting status; the Company’s NDA readiness activities and nonclinical studies, including their potential to support long-term dosing and enhance NVG-291’s profile for potential commercial use and future clinical expansion; the anticipated submission of the CONNECT SCI manuscript for peer-reviewed publication; the Company’s participation in investor conferences; the Company’s anticipated transition to U.S. domestic issuer reporting status, preparation of financial statements under U.S. GAAP and filing of an Annual Report on Form 10-K for fiscal year 2026; the development and potential therapeutic benefits of the Company’s product candidates; and other factors described in the “Risk Factors” section of the Company’s most recently filed Annual Information Form and Annual Report on Form 40-F/A, its amended and restated management’s discussion and analysis for the year ended December 31, 2025, and subsequent filings with Canadian securities regulators and the U.S. Securities and Exchange Commission. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the SEC’s website at www.sec.gov. Readers should not place undue reliance on forward-looking statements made in this news release. Unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contacts
On365 Partners, Investor Relations
ir@nervgen.com
203.293.8091


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does NervGen expect Phase 3 RESTORE results?

NervGen expects topline RESTORE results in the first half of 2028, following expected enrollment completion in the second half of 2027. Enrollment is ongoing after the first participant was dosed in October 2026.

How much cash does NervGen have to fund NVG-291 development?

NervGen had C$80.1 million (US$56.5 million) in cash and cash equivalents at September 30, 2026. Based on its current operating plan, the company believes this will fund operations through the anticipated RESTORE topline readout in the first half of 2028.

What additional nonclinical work is NervGen conducting for NVG-291?

A chronic toxicology study is ongoing as part of work intended to support NVG-291 dosing beyond 12 weeks and future clinical expansion. Preliminary embryofetal development studies have been completed successfully.

What did NervGen's completed financial restatement change?

The restatement revised certain warrant and option valuations and accounting for share issuance costs. Completed in October 2026, it covered the 2025 audited annual statements and the interim statements for the three and six months ended June 30, 2026. Adjustments were non-cash and did not affect cash, cash runway or business operations.

Is NervGen ending its at-the-market share offering program?

NervGen’s at-the-market program will be terminated on December 25, 2026, ahead of its expected transition to U.S. domestic issuer reporting status. No common shares had been sold under the program through November 16, 2026. The company expects to begin U.S. GAAP reporting with its fiscal 2026 Form 10-K.

Keep reading